Dr Reddys Lab voluntarily recalls few lots of Ranitidine tablets from US

23 Aug 2013 Evaluate

Pharma major Dr Reddys Laboratories has recalled few lots of Ranitidine Hydrochloride tablets of 150 mg strength in the US earlier this month due to microbial contamination of non-sterile products. It is a class II recall by the company. The drug was supplied to three different parties with three different brand names. The product was manufactured at the company’s facility in Shreveport, USA.

Ranitidine, an over the counter (OTC) drug, is indicated for short-term treatment of active duodenal ulcer and also used to treat heart burn and acid indigestion.

Dr Reddys is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.

Dr. Reddys Lab Share Price

1275.05 -1.95 (-0.15%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×